Lilly lung cancer med up for FDA panel review; AZ, Ironwood eye China filing for Linzess;

> Eli Lilly's ($LLY) experimental lung cancer drug nectumumab is set for an FDA advisory panel meeting Thursday, with agency reviewers asking the expert members to address the drug's blood-clotting risks. Report

> AstraZeneca ($AZN) and partner Ironwood ($IRWD) said their constipation drug Linzess met its goals in a new trial aimed at a regulatory filing in China. Report

> Sanofi ($SNY) is taking two new malaria combo treatments into Phase IIb trials, with one of the artemisinin-free meds--OZ439/Piperquine--already in study and the other--OZ439/Ferroquine--set to start this summer. Release | Report

> Eisai rolled out its epilepsy drug Fycompa for a new indication in the U.K., for another type of seizures. Report

> Hi-Tech Pharmaceuticals snapped up another company in the nutrition and weight loss field, Innovative Laboratories, to expand in diet remedies in the U.S. Release

> Novo Nordisk ($NVO) picked up a set of awards for its investor relations work, including a best-in-class nod for large-cap companies in Europe. Report

And Finally... Oregon has dramatically expanded women's access to birth control. Report

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.